Trial Profile
A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Troriluzole (Primary)
- Indications Obsessive-compulsive disorders
- Focus Proof of concept; Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceuticals
- 28 Aug 2023 Planned End Date changed from 14 Mar 2024 to 1 Sep 2024.
- 09 Mar 2023 Planned End Date changed from 14 Mar 2023 to 14 Mar 2024.
- 03 Aug 2022 Planned End Date changed from 21 Apr 2023 to 14 Mar 2023.